Exploring the Therapeutic Promise of MZE782 First-in-Human Phase 1 Results of a Novel SLC6A19 Inhibitor for Phenylk...
Maze Therapeutics has recently announced promising first-in-human results from a Phase 1 clinical trial of MZE782, a novel oral SLC6A19 inhibitor. This groundbreaking research shows potential implications for the treatm...
Sep 11, 2025
• Biotechnology & Pharmaceuticals Industry
Clinical Study
